Wall Street brokerages expect Agile Therapeutics Inc (NASDAQ:AGRX) to announce ($0.11) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Agile Therapeutics’ earnings, with estimates ranging from ($0.13) to ($0.10). Agile Therapeutics posted earnings per share of ($0.21) during the same quarter last year, which indicates a positive year-over-year growth rate of 47.6%. The company is expected to report its next quarterly earnings results on Monday, May 6th.

According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.66) to ($0.34). For the next financial year, analysts expect that the business will report earnings of ($0.48) per share, with EPS estimates ranging from ($0.79) to $0.11. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04.

A number of brokerages have recently weighed in on AGRX. ValuEngine raised shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 11th. Maxim Group reissued a “buy” rating and set a $3.00 price objective on shares of Agile Therapeutics in a report on Monday, February 11th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Agile Therapeutics in a report on Friday, January 11th.

Shares of AGRX opened at $1.61 on Tuesday. The firm has a market cap of $57.41 million, a PE ratio of -2.78 and a beta of 0.36. Agile Therapeutics has a 1-year low of $0.23 and a 1-year high of $3.24.

Several institutional investors and hedge funds have recently made changes to their positions in AGRX. BlackRock Inc. lifted its position in Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 18,038 shares during the period. Geode Capital Management LLC lifted its position in Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 44,639 shares during the period. Acadian Asset Management LLC lifted its position in Agile Therapeutics by 260.7% during the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after purchasing an additional 226,255 shares during the period. Fosun International Ltd acquired a new position in Agile Therapeutics during the third quarter valued at $180,000. Finally, Renaissance Technologies LLC lifted its position in Agile Therapeutics by 54.3% during the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock valued at $449,000 after purchasing an additional 430,907 shares during the period. 42.15% of the stock is currently owned by hedge funds and other institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Read More: Asset Allocation

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.